Insulina inalável: desenvolvimento de dispositivo tecnológico

Detalhes bibliográficos
Ano de defesa: 2024
Autor(a) principal: Matos, Igor Leonardo Santos
Orientador(a): Borges, Lysandro Pinto
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Não Informado pela instituição
Programa de Pós-Graduação: Pós-Graduação Profissional em Gestão e Inovação Tecnológica em Saúde
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Palavras-chave em Inglês:
Link de acesso: https://ri.ufs.br/jspui/handle/riufs/22479
Resumo: Introduction: Diabetes is a chronic disease with a growing impact on global public health, with projections indicating that by 2045, 783 million people will be living with the condition. Effective glycemic control is essential to prevent complications, but treatment adherence faces challenges, especially among patients using injectable insulin, which is often associated with discomfort and negative perceptions. In this context, inhaled insulin emerges as a less invasive and more practical alternative. Although devices like Exubera® and Afrezza® have pioneered this field, they still face limitations in acceptance and adverse effects, such as coughing and throat irritation, possibly due to suboptimal inhaler designs. Objective: To develop an optimized dry powder inhaler (DPI) for the effective and uniform administration of insulin to diabetic patients. Methods: A literature review on DPIs was conducted to identify advancements and limitations. The Venturi effect was applied to the design to accelerate airflow through a narrow channel, promoting effective insulin powder atomization and facilitating absorption. The modeling was performed using Fusion 360® software, enabling the creation of a 3D prototype and visualization of structural mechanism details. Device development: The device was designed to accommodate patients with respiratory and motor difficulties. The dimensions of the channel and airflow velocity were adjusted to achieve a rate of 64 liters/hour, ensuring efficient dispersion of particles ranging from 2 to 5 micrometers. Key components include an enlarged suction mouthpiece and an adjustable Venturi shaft to facilitate administration. Results and Discussion: The inhaler was designed to optimize the administration of inhalable insulin, ensuring uniform particle dispersion between 2 and 5 micrometers, with good ergonomics, medium intrinsic resistance, and reduced costs. The device offers technical and commercial advantages, including improved dispersion, reduced respiratory tract irritation, and protection through a utility model patent. Conclusion: Diabetes represents a costly challenge for healthcare systems and patients. Inhalable insulin devices have the potential to improve treatment adherence, despite existing shortcomings. Thus, a 3D model of an optimized inhaler for insulin use was developed based on the Venturi effect and subsequently submitted for a utility model patent at the INPI.
id UFS-2_976c30c084ddedb5770ef54071bd9b0e
oai_identifier_str oai:oai:ri.ufs.br:repo_01:riufs/22479
network_acronym_str UFS-2
network_name_str Repositório Institucional da UFS
repository_id_str
spelling Matos, Igor Leonardo SantosBorges, Lysandro Pinto2025-06-25T11:51:47Z2025-06-25T11:51:47Z2024MATOS, Igor Leonardo Santos. Insulina inalável: desenvolvimento de dispositivo tecnológico. 2024. 51f. Dissertação (Mestrado em Gestão e Inovação Tecnológica em Saúde) - Universidade Federal de Sergipe, Aracaju, 2024.https://ri.ufs.br/jspui/handle/riufs/22479Introduction: Diabetes is a chronic disease with a growing impact on global public health, with projections indicating that by 2045, 783 million people will be living with the condition. Effective glycemic control is essential to prevent complications, but treatment adherence faces challenges, especially among patients using injectable insulin, which is often associated with discomfort and negative perceptions. In this context, inhaled insulin emerges as a less invasive and more practical alternative. Although devices like Exubera® and Afrezza® have pioneered this field, they still face limitations in acceptance and adverse effects, such as coughing and throat irritation, possibly due to suboptimal inhaler designs. Objective: To develop an optimized dry powder inhaler (DPI) for the effective and uniform administration of insulin to diabetic patients. Methods: A literature review on DPIs was conducted to identify advancements and limitations. The Venturi effect was applied to the design to accelerate airflow through a narrow channel, promoting effective insulin powder atomization and facilitating absorption. The modeling was performed using Fusion 360® software, enabling the creation of a 3D prototype and visualization of structural mechanism details. Device development: The device was designed to accommodate patients with respiratory and motor difficulties. The dimensions of the channel and airflow velocity were adjusted to achieve a rate of 64 liters/hour, ensuring efficient dispersion of particles ranging from 2 to 5 micrometers. Key components include an enlarged suction mouthpiece and an adjustable Venturi shaft to facilitate administration. Results and Discussion: The inhaler was designed to optimize the administration of inhalable insulin, ensuring uniform particle dispersion between 2 and 5 micrometers, with good ergonomics, medium intrinsic resistance, and reduced costs. The device offers technical and commercial advantages, including improved dispersion, reduced respiratory tract irritation, and protection through a utility model patent. Conclusion: Diabetes represents a costly challenge for healthcare systems and patients. Inhalable insulin devices have the potential to improve treatment adherence, despite existing shortcomings. Thus, a 3D model of an optimized inhaler for insulin use was developed based on the Venturi effect and subsequently submitted for a utility model patent at the INPI.Introdução: A diabetes é uma doença crônica com impacto crescente na saúde pública global, projetando-se que até 2045, 783 milhões de pessoas estejam convivendo com a condição. O controle eficaz da glicemia é essencial para prevenir complicações, mas a adesão ao tratamento enfrenta desafios, principalmente em pacientes que usam insulina injetável, que é frequentemente associada a desconfortos e percepções negativas pelos pacientes. Nesse contexto, a insulina inalada se apresenta como uma alternativa menos invasiva e prática. Embora dispositivos como Exubera® e Afrezza® tenham inovado nesse campo, eles ainda enfrentam limitações de aceitação e efeitos adversos, como tosse e irritação na garganta, possivelmente devido à falta de otimização dos inaladores. Objetivo: Desenvolver um inalador de pó seco (Dry Powder Inhaler - DPI) otimizado para a administração eficaz e uniforme de insulina em pacientes com diabetes. Métodos: Realizou-se uma revisão da literatura sobre os DPI para identificar avanços e limitações. O efeito Venturi foi aplicado ao design para acelerar o fluxo de ar em um canal estreito, promovendo a atomização eficaz da insulina em pó e facilitando sua absorção. A modelagem foi realizada no programa de computador Fusion 360®, que foi possível criar um protótipo em 3D visualizando os detalhes dos mecanismos estruturais. Criação e desenvolvimento do dispositivo: O dispositivo foi projetado, buscando inclusive atender pacientes com dificuldades respiratórias e motoras. As dimensões do canal e a velocidade do fluxo foram ajustadas para atingir uma taxa de 64 Litros/hora, garantindo uma dispersão eficaz de partículas de 2 a 5 micrômetros. Componentes-chave incluem um bocal de sucção ampliado e uma haste de Venturi ajustada, que facilita a administração. Resultados e discussão: O inalador foi projetado para otimizar a administração de insulina inalável, garantir uniforme dispersão de partículas entre 2 e 5 micrômetros, com boa ergonomia, média resistência intrínseca e custo reduzido. O dispositivo oferece vantagens técnicas e comerciais, incluindo melhor dispersão, redução de irritações no trato respiratório, além de ser protegido por patente de modelo de utilidade. Conclusão: A diabetes representa um desafio oneroso para os sistemas de saúde e aos pacientes. Dispositivos de insulina inalável têm o potencial de melhorar a adesão ao tratamento apesar dos existentes terem falhas. Sendo assim, foi desenvolvida a modelagem tridimensional de um inalador, um dispositivo inalável otimizado para o uso com insulina a partir do efeito Venturi que posteriormente foi submetido à patente de modelo de utilidade no INPI.AracajuporDiabetes mellitusInsulina inalávelDispositivo inaladorInalador de pó secoVenturiDiabetes mellitusInhalable insulinInhaler deviceDry powder inhalerVenturiInsulina inalável: desenvolvimento de dispositivo tecnológicoinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisPós-Graduação Profissional em Gestão e Inovação Tecnológica em SaúdeUniversidade Federal de Sergipereponame:Repositório Institucional da UFSinstname:Universidade Federal de Sergipe (UFS)instacron:UFSinfo:eu-repo/semantics/openAccessLICENSElicense.txtlicense.txttext/plain; charset=utf-81475https://ri.ufs.br/jspui/bitstream/riufs/22479/1/license.txt098cbbf65c2c15e1fb2e49c5d306a44cMD51ORIGINALDissertacao_Igor_Leonardo_Santos_Matos.pdfDissertacao_Igor_Leonardo_Santos_Matos.pdfapplication/pdf946851https://ri.ufs.br/jspui/bitstream/riufs/22479/2/Dissertacao_Igor_Leonardo_Santos_Matos.pdf843095a45b32e261dae4a2a70480436eMD52riufs/224792025-06-25 08:51:52.964oai:oai:ri.ufs.br:repo_01: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Repositório InstitucionalPUBhttps://ri.ufs.br/oai/requestrepositorio@academico.ufs.bropendoar:2025-06-25T11:51:52Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)false
dc.title.pt_BR.fl_str_mv Insulina inalável: desenvolvimento de dispositivo tecnológico
title Insulina inalável: desenvolvimento de dispositivo tecnológico
spellingShingle Insulina inalável: desenvolvimento de dispositivo tecnológico
Matos, Igor Leonardo Santos
Diabetes mellitus
Insulina inalável
Dispositivo inalador
Inalador de pó seco
Venturi
Diabetes mellitus
Inhalable insulin
Inhaler device
Dry powder inhaler
Venturi
title_short Insulina inalável: desenvolvimento de dispositivo tecnológico
title_full Insulina inalável: desenvolvimento de dispositivo tecnológico
title_fullStr Insulina inalável: desenvolvimento de dispositivo tecnológico
title_full_unstemmed Insulina inalável: desenvolvimento de dispositivo tecnológico
title_sort Insulina inalável: desenvolvimento de dispositivo tecnológico
author Matos, Igor Leonardo Santos
author_facet Matos, Igor Leonardo Santos
author_role author
dc.contributor.author.fl_str_mv Matos, Igor Leonardo Santos
dc.contributor.advisor1.fl_str_mv Borges, Lysandro Pinto
contributor_str_mv Borges, Lysandro Pinto
dc.subject.por.fl_str_mv Diabetes mellitus
Insulina inalável
Dispositivo inalador
Inalador de pó seco
Venturi
topic Diabetes mellitus
Insulina inalável
Dispositivo inalador
Inalador de pó seco
Venturi
Diabetes mellitus
Inhalable insulin
Inhaler device
Dry powder inhaler
Venturi
dc.subject.eng.fl_str_mv Diabetes mellitus
Inhalable insulin
Inhaler device
Dry powder inhaler
Venturi
description Introduction: Diabetes is a chronic disease with a growing impact on global public health, with projections indicating that by 2045, 783 million people will be living with the condition. Effective glycemic control is essential to prevent complications, but treatment adherence faces challenges, especially among patients using injectable insulin, which is often associated with discomfort and negative perceptions. In this context, inhaled insulin emerges as a less invasive and more practical alternative. Although devices like Exubera® and Afrezza® have pioneered this field, they still face limitations in acceptance and adverse effects, such as coughing and throat irritation, possibly due to suboptimal inhaler designs. Objective: To develop an optimized dry powder inhaler (DPI) for the effective and uniform administration of insulin to diabetic patients. Methods: A literature review on DPIs was conducted to identify advancements and limitations. The Venturi effect was applied to the design to accelerate airflow through a narrow channel, promoting effective insulin powder atomization and facilitating absorption. The modeling was performed using Fusion 360® software, enabling the creation of a 3D prototype and visualization of structural mechanism details. Device development: The device was designed to accommodate patients with respiratory and motor difficulties. The dimensions of the channel and airflow velocity were adjusted to achieve a rate of 64 liters/hour, ensuring efficient dispersion of particles ranging from 2 to 5 micrometers. Key components include an enlarged suction mouthpiece and an adjustable Venturi shaft to facilitate administration. Results and Discussion: The inhaler was designed to optimize the administration of inhalable insulin, ensuring uniform particle dispersion between 2 and 5 micrometers, with good ergonomics, medium intrinsic resistance, and reduced costs. The device offers technical and commercial advantages, including improved dispersion, reduced respiratory tract irritation, and protection through a utility model patent. Conclusion: Diabetes represents a costly challenge for healthcare systems and patients. Inhalable insulin devices have the potential to improve treatment adherence, despite existing shortcomings. Thus, a 3D model of an optimized inhaler for insulin use was developed based on the Venturi effect and subsequently submitted for a utility model patent at the INPI.
publishDate 2024
dc.date.issued.fl_str_mv 2024
dc.date.accessioned.fl_str_mv 2025-06-25T11:51:47Z
dc.date.available.fl_str_mv 2025-06-25T11:51:47Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv MATOS, Igor Leonardo Santos. Insulina inalável: desenvolvimento de dispositivo tecnológico. 2024. 51f. Dissertação (Mestrado em Gestão e Inovação Tecnológica em Saúde) - Universidade Federal de Sergipe, Aracaju, 2024.
dc.identifier.uri.fl_str_mv https://ri.ufs.br/jspui/handle/riufs/22479
identifier_str_mv MATOS, Igor Leonardo Santos. Insulina inalável: desenvolvimento de dispositivo tecnológico. 2024. 51f. Dissertação (Mestrado em Gestão e Inovação Tecnológica em Saúde) - Universidade Federal de Sergipe, Aracaju, 2024.
url https://ri.ufs.br/jspui/handle/riufs/22479
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.program.fl_str_mv Pós-Graduação Profissional em Gestão e Inovação Tecnológica em Saúde
dc.publisher.initials.fl_str_mv Universidade Federal de Sergipe
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFS
instname:Universidade Federal de Sergipe (UFS)
instacron:UFS
instname_str Universidade Federal de Sergipe (UFS)
instacron_str UFS
institution UFS
reponame_str Repositório Institucional da UFS
collection Repositório Institucional da UFS
bitstream.url.fl_str_mv https://ri.ufs.br/jspui/bitstream/riufs/22479/1/license.txt
https://ri.ufs.br/jspui/bitstream/riufs/22479/2/Dissertacao_Igor_Leonardo_Santos_Matos.pdf
bitstream.checksum.fl_str_mv 098cbbf65c2c15e1fb2e49c5d306a44c
843095a45b32e261dae4a2a70480436e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)
repository.mail.fl_str_mv repositorio@academico.ufs.br
_version_ 1851759417228263424